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P U B L I S H E D B Y E L S E V I E R I N C .LettersHigh-Intensity Interval
Exercise Effectively
Improves Cardiac
Function in Patients With
Type 2 Diabetes Mellitus
and Diastolic Dysfunction
A Randomized Controlled TrialLeft ventricular diastolic dysfunction (DD) may lead
to heart failure and is found in approximately 50% of
asymptomatic patients with type 2 diabetes mellitus
(T2DM). Little is known about the effect of exercise
on DD in T2DM (1), but moderate-intensity exercise
(MIE) seems insufﬁcient to improve myocardial
function. Studies indicate that high-intensity interval
exercise (HIIE) is more effective than MIE in reducing
cardiovascular risk factors in T2DM and in reversing
left ventricular remodeling in patients with post-
infarction heart failure. The aim of this study was to
compare the effect of HIIE (4  4–min interval, 90% to
95% maximal heart rate, 40 min/bout, 3/week) and
MIE according to current guidelines ($10 min/bout,
210 min/week) on DD, deﬁned as peak early diastolic
tissue Doppler velocity (e0) <8 cm/s (2), and other
cardiovascular risk factors in patients with T2DM and
DD. Our hypothesis was that HIIE, more than MIE,
would improve these measures.
We prescreened 83 patients for DD who had T2DM
for <10 years and no known cardiovascular disease. A
total of 47 patients (55.9  6.0 years; 36% female;
duration of T2DM: 3.6  2.5 years) met the inclusion
criteria (e0 <8 cm/s). The subjects were randomized to
home-based MIE (n ¼ 23) and supervised HIIE (n ¼ 24)
and tested at baseline, 12 weeks (MIE, n ¼ 17; HIIE, n ¼
20), and 1 year (MIE, n ¼ 16; HIIE, n ¼ 16). The patients
in the MIE group were younger than those in the HIIE
group (mean 54.7  5.3 vs. 58.6  5.0 years) but did not
differ by sex (35.3% vs. 40.0% female) or duration of
T2DM (3.0  2.6 vs. 4.2  2.3 years). After 12 weeks,
exercise was home based in both groups.
Repeated-measures analysis of variance models
(generalized linear model, linear mixed model) were
applied to compare intervention groups with respectto mean change in outcome variables. Results from
baseline to 12 weeks are shown in Table 1.
Both groups showed improved diastolic function
(e0) at rest, but HIIE showed more improvement than
MIE. Only HIIE improved transmitral peak early dia-
stolic velocity (E), diastolic ﬁlling pressure (E/e0), and
E/A ratio. A higher proportion of patients in the HIIE
group had improved diastolic function to e0 >8 cm/s
during the 12-week period (80.0% vs. 41.2%; p ¼ 0.02,
chi-square test). During exercise, only HIIE improved
diastolic function (E). Lack of improvement in e0
during exercise may be explained by the use of
different echocardiographic methods at rest and
during exercise.
A nonsigniﬁcant decrease in e0 at rest was seen
from 12 weeks to 1 year (0.45 and 0.24 cm/s for
HIIE and MIE, respectively). However, in contrast to
the MIE group, the HIIE group still had improved
diastolic function (e0) compared with baseline.
Improvement in E was sustained in the HIIE group
after 1 year.
After 12 weeks, HIIE but not MIE improved systolic
function at rest (peak systolic tissue Doppler velocity,
S0; global strain and global strain rate) and during
exercise (global strain rate).
At baseline, mean peak oxygen consumption
(VO2peak) (n ¼ 37) was approximately 16% lower
compared with a healthy population (the Nord-
Trøndelag Health Study [HUNT] study). Both inter-
vention groups increased VO2peak, but HIIE did so more
thanMIE. The improvement inVO2peakwas sustained at
1 year in the HIIE group, but not in the MIE group,
despite a signiﬁcant decrease from 12 weeks to 1 year
(1.68 vs. 0.19 ml/kg/min, respectively).
After 12 weeks, waist circumference was reduced in
both groups, whereas only HIIE reduced body mass
index. From 12 weeks to 1 year, the MIE group, but not
the HIIE group, had increased waist circumference
(2.01 vs. 0.12 cm) and tended toward increased body
mass index (0.58 vs. 0.12 kg/m2). Body fat percent
did not improve after 12 weeks but was reduced in
the HIIE group after 1 year (mean change 1.31%).
Twelve weeks of HIIE improved ﬂow-mediated dila-
tion (incomplete data due to impaired ultrasound
image quality), hemoglobin A1c, and high-sensitivity
C-reactive protein level. Improved ﬂow-mediated
dilation and hemoglobin A1c were not sustained
TABLE 1 Baseline and 12-Week Post-Test Results for Diastolic Echocardiographic Variables at Rest
MIE (n ¼ 17)
p Value*
HIIE (n ¼ 20)
p Value*
MIE vs. HIIE
N Baseline 12 Weeks Difference n Baseline 12 Weeks Difference p Interaction†
DD classiﬁcation
Mild (grade I) 17 5 (29.4) 20 1 (5.0)
Moderate (grade II) 17 12 (70.6) 20 18 (90)
Severe (grade III) 17 0 (0.0) 20 1 (5.0)
Diastolic function, supine
E, cm/s 14 63.4  9.5 64.4  13.4 1.0  14.0 0.78 20 64.8  10.7 75.1  15.8 10.3  12.7 0.002 0.05
e0, cm/s 17 7.1  0.7 7.6  1.1 0.5  0.7 0.02 20 7.0  0.7 8.8  1.2 1.8  1.1 <0.001 <0.001
E/e0 14 9.1  1.8 8.6  1.9 0.5  1.6 0.28 20 9.3  1.7 8.6  1.9 0.7  1.5 0.05 0.67
E/A, ratio 14 0.92  0.18 0.99  0.21 0.07  0.23 0.28 20 0.93  0.21 1.07  0.26 0.13  0.18 0.003 0.36
Systolic function, supine
S0, cm/s 14 7.7  1.2‡ 7.6  1.0 0.1  1.1 0.76 20 6.8  0.8‡ 7.8  1.5 0.9  1.4 0.007 0.03
Global strain, % 15 16.7  2.2 16.4  2.1 0.3  1.6 0.51 20 17.2  1.9 18.2  2.2 1.0  1.9 0.03 0.05
Global strain rate, s1 16 1.00  0.15‡ 0.95  0.10 0.06  0.23 0.14 20 0.87  0.11‡ 0.97  0.13 0.10  0.17 0.03 0.009
VO2peak
ml/kg/min 16 33.2  7.4 34.4  7.7 1.2  2.2 0.04 20 31.5  6.1 35.6  6.3 4.1  2.9 <0.001 0.002
ml/kg0.75/min 16 102.0  23.8 105.2  23.9 3.2  6.1 0.06 20 98.6  17.7 110.4  20.0 11.8  9.5 <0.001 0.003
l/min 16 2.96  0.81 3.0  0.79 0.06  0.17 0.17 20 2.96  0.57 3.29  0.68 0.33  0.29 <0.001 0.003
FMD
FMD, % 10 13.0  9.8 13.0  9.9 0.0  6.2 0.99 17 9.2  9.6 18.5  9.6 9.2  11.2 0.004 0.03
FMDnorm, % 10 13.7  12.6 14.6  19.3 1.0  10.0 0.76 16 8.9  11.4 22.8  15.1 13.9  18.5 0.009 0.05
Heart rate, beats/min
Rest 16 74  10‡ 72  8 2  8 0.39 19 68  8‡ 66  9 1  8 0.48 0.84
Maximal 16 168  17 170  14 2  4 0.10 20 167  10 169  10 2  4 0.08 0.85
Blood pressure, mm Hg
Systolic 17 135.4  11.9 134.9  14.8 0.5  11.9 0.87 20 142.1  18.3 142.5  20.6 0.5  15.8 0.90 0.85
Diastolic 17 80.9  7.1 80.8  6.6 0.1  5.8 0.97 20 81.7  6.9 78.3  9.0 3.4  9.3 0.12 0.21
Biochemical values
HbA1c, % 16 6.7  0.7 6.5  0.6 0.2  0.7 0.30 20 7.0  1.2 6.6  0.9 0.4  0.5 0.007 0.36
HbA1c, mmol/mol 16 50.0  5.2 48.0  4.4 2.0  7.0 0.30 20 53.0  9.1 49.0  6.7 4.0  5.0 0.007 0.36
HOMA-IR 15 2.6  1.0 2.5  0.9 0.1  0.5 0.32 20 2.7  0.7 2.7  1.0 0.0  0.8 1.0 0.61
hs-CRP, mg/l 16 1.6  1.2‡ 1.6  1.2 0.1  1.3 0.86 19 3.7  2.8‡ 2.1  1.3 1.6  2.6 0.02 0.04
Anthropometric values
BMI, m/kg2 17 29.7  3.7 29.4  3.8 0.3  0.8 0.13 20 30.2  2.8 29.7  2.4 0.5  0.7 0.009 0.52
WC, cm 17 106.5  8.7 104.5  7.3 2.0  2.5 0.005 20 108.6  7.7 106.0  6.8 2.6  2.9 0.001 0.55
Body fat, % 15 27.5  7.3 27.2  6.7 0.3  2.1 0.58 19 27.9  7.7 27.6  8.5 0.3  1.3 0.36 0.97
Values are n (%) or mean  SD. *p value: within-group difference. †p value: difference in mean change between groups. ‡Difference between groups at baseline, p < 0.05.
A ¼ transmitral late diastolic velocity; BMI ¼ body mass index; DD ¼ diastolic dysfunction; E ¼ transmitral peak early diastolic velocity; e0 ¼ peak early diastolic tissue Doppler velocity; FMD ¼ ﬂow-
mediated dilation of the brachial artery; FMDnorm ¼ FMD normalized, FMD/shear rate (mean ﬂow/mean diameter); HbA1c ¼ glycosylated hemoglobin; HIIE ¼ high-intensity interval exercise; HOMA-IR ¼
homeostatic model assessment of insulin resistance; hs-CRP ¼ high-sensitive C-reactive protein; MIE ¼ moderate-intensity exercise; S0 ¼ peak systolic tissue Doppler velocity; VO2peak ¼ peak oxygen
consumption; WC ¼ waist circumference.
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1759after 1 year. No signiﬁcant changes were seen for
other variables.
Limitations of this study include the small size,
signiﬁcant dropout rate (albeit similar to other
studies in this arena), lack of a control group without
exercise, and supervised exercise in only the HIIE
group, which could introduce better compliance.
This pilot evaluation, one of the ﬁrst randomized
studies to assess the effect of exercise intensity on DD
in patients with T2DM, shows that HIIE may modify
the natural history of diabetic cardiac dysfunction. In
patients with T2DM and DD, HIIE was more effective
than MIE in improving diastolic and systolic functionas well as VO2peak. This indicates that exercise in-
tensity is an important factor in improving cardiac
function in early stages of T2DM and DD. Larger
studies in the future should explore whether this is an
effective and low-cost intervention in these patients
with few other good therapeutic options.Siri M. Hollekim-Strand, MSc
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of Atherosclerosis
Why Are Exercise and Physical Activity Not
Getting the Respect They Deserve?The role of regular exercise and/or adequate amounts
of physical activity in the prevention and control
of cardiovascular diseases and its risk factors has
been ﬁrmly established by a variety of epidemiolog-
ical and interventional studies (1). However, with
respect to the primary prevention and management
of atherosclerosis, there has been little attention to
the effects of exercise on plaque size, stability, and
regression. There are published data on the potential
beneﬁts of exercise on atherosclerotic plaque and
its regression (2); however, despite such evidence,
statins continue to monopolize atherosclerosis pre-
vention programs.
Robinson and Gidding (3) recently published a re-
view recommending that curing atherosclerosis
should be the next goal of cardiovascular prevention.
We agree with the authors that this is deﬁnitely
an important goal, but is initiating statins at such
early ages the best approach? The authors provide
compelling evidence that suggest the beneﬁts of
early initiation of statins on various atherosclerotic
progression pathways. Even though this suggests
that there could be beneﬁts in high-risk groups
with statins, it is important to realize that there is
still a strong need to promote active lifestylesamong children. A recent report by Palmefors et al.
(2) found signiﬁcant evidence supporting the bene-
ﬁts of physical activity on tumor necrosis factor a
levels, C-reactive protein levels, endothelial pro-
genitor cells, and, with aerobic exercise, intercel-
lular adhesion molecule 1 levels. However, these
ﬁndings have not found their way into prevention
guidelines.
In an accompanying report, Daniels (4) also sug-
gested the need for lifestyle interventions to help
control the atherosclerotic cascade. As currently
understood, the risk of cardiovascular disease
cannot be attributable to only dyslipidemia (espe-
cially elevated low-density lipoprotein levels, which
is the target for statins) but also involves a host of
other risk factors. Therefore, effective prevention
strategies cannot target only one dimension (i.e.,
increased low-density lipoprotein levels) but should
focus on other modiﬁable risk factors that, in our
opinion, can be addressed best through lifestyle in-
terventions. Regular exercise and physical activity
produce numerous health beneﬁts (e.g., antiathero-
sclerotic, antithrombotic, anti-ischemic, antiar-
rhythmic, and psychological effects), thereby acting
as a “polypill”. In fact, these beneﬁts supersede the
effects obtained through pharmacotherapy and are
also cost-effective and free from adverse events (5).
In this regard, we would like to emphasize a few
steps in working toward the prevention and/or
management of atherosclerosis through exercise and
physical activity.
1. Promoting high-energy expenditure through pro-
per diet and structured exercise training and
physical activity to promote plaque stability (1,500
kcal/week) and reversal (>2,000 kcal/week)
2. Promoting an active lifestyle at home
a. Moving away from video games and the Internet
to playing outdoors in parks, walking, and using
stairs
3. Promoting an active lifestyle at school
a. Improving participation in physical education
and tailoring programs to suit the needs and
interests of children for optimal health beneﬁts
b. Emphasizing the need for excellence in sports in
addition to academic excellence
4. Promoting healthy food habits at home, school,
and public places
It is our opinion that encouraging such healthy be-
haviors early in life will facilitate improvements
with regard to cardiovascular-related events and help
curb the rise in the incidence of childhood obesity and
type 2 diabetes mellitus. There is, however, a strong
